Advancing Interventional Oncology: Trials in Progress

Coordinator(s)

• KG

  Kirema Garcia-Reyes, MD

  Assistant Professor
  Mount Sinai, United States

Interventional Oncology is in the midst of rapid evolution, with multiple phase II/III clinical trials poised to define the role of IR therapies across tumor types. This session will highlight active and upcoming IO trials, organized by disease focus—including liver, lung, renal, metastases, and emerging or competitive spaces. Faculty will synthesize the major studies within their area, providing attendees with a clear roadmap of the current IO research landscape and insight into the pivotal results expected to shape practice in the near future.

Presentations:

• 8:30 AM - 8:40 AM ET

  Redefining HCC: Ongoing Trials and Combination Strategies
  

  Co-Speaker: Venkatesh P. Krishnasamy, MD (he/him/his) – University of Alabama at Birmingham
• 8:40 AM - 8:50 AM ET

  Locoregional and Systemic Integration for Liver Metastases: Trials in Progress
  

  Speaker: Zachary Berman, MD – University of California, San Diego
• 8:50 AM - 9:00 AM ET

  Trials and Emerging Data in Lung Cancer Ablation and IO
  

  Speaker: Matthew R. Callstrom, MD, FSIR
• 9:00 AM - 9:10 AM ET

  Expanding the Role of IR in Renal Tumors: Ongoing Trials and Emerging Data
  

  Speaker: Andrew Gunn, MD – University of Kentucky
• 9:10 AM - 9:20 AM ET

  Emerging Frontiers: Trials Expanding IO Beyond Traditional Tumor Types
  

  Speaker: Nadine Abi-Jaoudeh, MD, FSIR (she/her/hers) – University of California
• 9:20 AM - 9:30 AM ET

  Looking Ahead: Competitive Trials That May Reshape the IO Landscape
  

  Speaker: Nora Tabori, MD (she/her/hers) – MedStar Washington Hospital Center
• 9:30 AM - 9:45 AM ET

  Q&A